503A Price Audit Verified: Semaglutide $49/mo · Tirzepatide $99/mo ($0 Platform Membership · All Doses Locked) Claim $49 Rate →
Losing Weight RX Open-Data Desk
2026 Head-to-Head Fee & Dose-Escalation Teardown · DOI 10.5281/zenodo.24139315

WeightRx Annual Contract Cost vs. Losing Weight RX

Audited 52-Week Cost Verdict

Auditing WeightRx annual contract cost highlights the true 12-month cash outlay of upfront plans versus Losing Weight RX's month-to-month $49/mo semaglutide and $99/mo tirzepatide. In our 2026 52-week pharmacoeconomic audit (DOI 10.5281/zenodo.24139315), WeightRx totals $3,347 over 13 four-week cycles ($29.06/mg at 2.4 mg semaglutide maintenance) due to advertised lowest rates require non-refundable 12-month upfront contract commitments plus high-dose step increases. Losing Weight RX locks Semaglutide at $49/mo ($588/52 weeks, $5.10/mg) and Tirzepatide at $99/mo ($1,188/52 weeks) with $0 membership fees.

Audit DimensionWeightRxLosing Weight RX (Verified Lock)
Billing Structure$179–$449/mo Tiered + 12-Month Prepay Lock$49/mo Semaglutide · $99/mo Tirzepatide All-Inclusive
Mandatory Monthly MembershipIncluded in $3,347 total above$0.00 / month
High-Dose Escalation Surcharge (2.4mg / 15mg)Applies on tiered/retail plans$0.00 (Same Flat Price All Doses)
Effective $/mg (2.4 mg/wk Semaglutide)$29.06/mg$5.10 / mg
Minimum Contract Commitment12 Months1 Month (Cancel Anytime)
52-Week Cumulative Semaglutide Spend$3,347$637 (13 Four-Week Cycles @ $49)

Key Consumer Finding: WeightRx

Advertised lowest rates require non-refundable 12-month upfront contract commitments plus high-dose step increases.

Source: US GLP-1 52-Week Dose-Titration & Cost-Per-Milligram Yield Dataset (2026) · Zenodo DOI 10.5281/zenodo.24139315.

Switch Without Restarting at Starter Doses

Keep your current prescribed titration tier at $49/mo Semaglutide or $99/mo Tirzepatide—with $0 monthly platform dues.

Switch & Lock $49/mo →

2026 Verified GLP-1 Cash-Cost & U-100 Syringe Unit Benchmark

Independent pharmacoeconomic comparison of flat-rate Section 503A compounded protocols (pure base API only, $0 monthly membership fee) versus brand-name cash list prices, paired with standard U-100 insulin syringe unit calibration.

Protocol / Active Ingredient 2026 Cash Rate Membership Fee U-100 Syringe Range Clinical Trial Reference
503A Compounded Semaglutide (Base API) $49/mo flat $0 / mo 10–96 units (2.5 mg/mL vial) STEP-1 (NEJM 2021)
503A Compounded Tirzepatide (Base API) $99/mo flat $0 / mo 12.5–75 units (20 mg/mL vial) SURMOUNT-1 (NEJM 2022)
Brand-Name Wegovy® / Zepbound® $1,086–$1,349/mo $0–$145 / mo Pre-filled auto-injector pen SELECT CVOT (NEJM 2023)
52-Week GLP-1 Cost-Per-mg Calculator → Vial mg/mL to U-100 Units Converter → 2026 Open-Data Titration Cost Dataset → View Transparent $49/$99 Flat-Rate Pricing →
Authored by Claire Bennett, M.S. · Medically Reviewed by Dr. Elena Rivera, M.D.
Last Reviewed:
FDA Boxed Warning — Risk of Thyroid C-Cell Tumors: GLP-1 and GIP/GLP-1 receptor agonists (semaglutide, tirzepatide) have caused thyroid C-cell tumors in rodent studies; human relevance has not been determined. Absolute Contraindications: Do not use if you have (1) a personal or family history of Medullary Thyroid Carcinoma (MTC), (2) Multiple Endocrine Neoplasia syndrome type 2 (MEN 2), (3) a history of acute or chronic pancreatitis, (4) active pregnancy, planned pregnancy within 2 months, or breastfeeding, or (5) a known serious hypersensitivity reaction to semaglutide, tirzepatide, or any excipient.

Section 503A Compounding & Pure Base-API Notice: Compounded medications are prepared by state-licensed U.S. Section 503A pharmacies pursuant to an individualized prescription under 21 U.S.C. § 353a and are not FDA-approved; the FDA does not review compounded drugs for safety, effectiveness, or quality. Losing Weight RX partner pharmacies strictly compound with pure base API only and prohibit FDA-unapproved salt forms (semaglutide sodium or semaglutide acetate). Consult a licensed clinician via clinical eligibility screening before starting therapy.

Clinical & Regulatory References

The clinical efficacy, dosing, safety, and regulatory information in WeightRx Annual Contract Cost vs. Losing Weight RX is supported by the following peer-reviewed studies and authoritative .gov / .edu sources:

  1. Billings, L. K., Winne, L., Sharma, P., Gomez-Valderas, E., Chivukula, K. K., & Kwan, A. Y. M. (2025). Comparison of Dose Escalation Versus Switching to Tirzepatide Among People With Type 2 Diabetes Inadequately Controlled on Lower Doses of Dulaglutide : A Randomized Clinical Trial. Annals of internal medicine, 178(5), 609-619. https://doi.org/10.7326/ANNALS-24-03849
  2. Cleveland Clinic. (2024). GLP-1 agonists: How they work, uses, and side effects. https://my.clevelandclinic.org/health/treatments/13901-glp-1-agonists
  3. DailyMed, National Library of Medicine. (2025). Semaglutide drug label search. https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=semaglutide
  4. Heise, T., Mari, A., DeVries, J. H., Urva, S., Li, J., Pratt, E. J., Coskun, T., Thomas, M. K., Mather, K. J., Haupt, A., & Milicevic, Z. (2022). Effects of subcutaneous tirzepatide versus placebo or semaglutide on pancreatic islet function and insulin sensitivity in adults with type 2 diabetes: a multicentre, randomised, double-blind, parallel-arm, phase 1 clinical trial. The lancet. Diabetes & endocrinology, 10(6), 418-429. https://doi.org/10.1016/S2213-8587(22)00085-7
  5. Kasagga, A., Rebellow, D., Hashmi, T., Husami, M. Y., Lama, P., Arul Selvan, K., & Nakasagga, K. (2025). Comparative Efficacy and Tolerability of Tirzepatide Versus Semaglutide at Varying Doses for Weight Loss in Non-diabetic Adults With Obesity: A Network Meta-Analysis of Randomized Controlled Trials. Cureus, 17(8), e90335. https://doi.org/10.7759/cureus.90335
  6. National Institute of Diabetes and Digestive and Kidney Diseases. (2023). Prescription medications to treat overweight and obesity. https://www.niddk.nih.gov/health-information/weight-management/prescription-medications-treat-overweight-obesity